A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab and/or Ipilimumab in Advanced Solid Tumors

Trial Profile

A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab and/or Ipilimumab in Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Aug 2017

At a glance

  • Drugs BMS 986178 (Primary) ; Ipilimumab; Nivolumab
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 31 Jul 2017 Planned End Date changed from 20 May 2020 to 22 May 2020.
    • 11 May 2017 Number of arms changed from 3 to 7 and patient number also changed from 212 to435.
    • 11 May 2017 Planned number of patients changed from 212 to 435.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top